Taysha Gene Therapies, Inc. (TSHA)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
TSHA files amendment to correct and update prior SEC statements
**⚠️ Important Notice:** The provided input only contains the metadata for an SEC filing (`d942601dars.pdf`) but does not include the actual document text or PDF content. Therefore, I cannot summarize the specific details, financials, or commentary. However, as an expert financial analyst, I have p
TSHA details governance and board structure for annual shareholder meeting
# 📑 What This Document Is ✉️ This document is a Proxy Statement (DEF 14A), which is essentially a mandatory informational packet sent by Taysha Gene Therapies, Inc. to its stockholders. Think of it as the company's formal homework assignment for its annual shareholder meeting. 👉 Why it matters: T
SEC filings
All filings →Insider trades
All insider trades →Taysha Gene Therapies, Inc. has no reported insider trades in the last 90 days.